Literature DB >> 20634327

Value of the new bone classification system in pediatric renal osteodystrophy.

Sevcan A Bakkaloglu1, Katherine Wesseling-Perry, Renata C Pereira, Barbara Gales, He-Jing Wang, Robert M Elashoff, Isidro B Salusky.   

Abstract

BACKGROUND AND OBJECTIVES: Although lesions of renal osteodystrophy have traditionally been defined by bone turnover, alterations in skeletal mineralization and volume are also prevalent and may contribute to significant morbidity in patients with chronic kidney disease (CKD). The study presented here was undertaken to compare the traditional spectrum of renal osteodystrophy defined by bone turnover to a new classification system that includes T (turnover), M (mineralization), and V (volume) and to determine the value of biochemical parameters as predictors of specific TMV lesions. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Pediatric patients (n = 161) treated with peritoneal dialysis were enrolled into the study.
RESULTS: Increased bone turnover and abnormal mineralization were prevalent (57% and 48%, respectively); bone volume was normal or increased in all subjects. Predictive algorithms for different skeletal diagnoses were established by Classification and regression tree analysis. Serum parathyroid hormone (PTH) less than 400 pg/ml in combination with alkaline phosphatase values less than 400 IU/L provided the highest correct prediction rate for patients with both normal bone turnover and normal mineralization. Levels of PTH were higher and serum calcium levels were lower in patients with defective mineralization, irrespective of bone turnover.
CONCLUSIONS: Although no single biochemical marker is able to provide a complete assessment of renal osteodystrophy, a combination of serum calcium, alkaline phosphatase, and PTH levels may lead to a more precise noninvasive assessment of turnover and mineralization abnormalities in this population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634327      PMCID: PMC2974387          DOI: 10.2215/CJN.01330210

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  27 in total

1.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

2.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  S Moe; T Drüeke; J Cunningham; W Goodman; K Martin; K Olgaard; S Ott; S Sprague; N Lameire; G Eknoyan
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

3.  Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease.

Authors:  Jason DeVille; Micah L Thorp; Lois Tobin; Eeva Gray; Eric S Johnson; David H Smith
Journal:  Nephrology (Carlton)       Date:  2006-12       Impact factor: 2.506

4.  Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.

Authors:  I B Salusky; B D Kuizon; T R Belin; J A Ramirez; B Gales; G V Segre; W G Goodman
Journal:  Kidney Int       Date:  1998-09       Impact factor: 10.612

5.  Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Authors:  Isidro B Salusky; William G Goodman; Shobha Sahney; Barbara Gales; Ashley Perilloux; He-Jing Wang; Robert M Elashoff; Harald Jüppner
Journal:  J Am Soc Nephrol       Date:  2005-06-08       Impact factor: 10.121

6.  First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

Authors:  Kevin J Martin; Harald Jüppner; Donald J Sherrard; William G Goodman; Mark R Kaplan; George Nassar; Patricia Campbell; Mario Curzi; Chaim Charytan; Laura C McCary; Matthew D Guo; Stewart A Turner; David A Bushinsky
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

7.  Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.

Authors:  H H Malluche; G A Siami; C Swanepoel; G H Wang; H Mawad; S Confer; M Smith; R D Pratt; M-C Monier-Faugere
Journal:  Clin Nephrol       Date:  2008-10       Impact factor: 0.975

8.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

9.  Low bone volume--a risk factor for coronary calcifications in hemodialysis patients.

Authors:  Teresa Adragao; Johann Herberth; Marie-Claude Monier-Faugere; Adam J Branscum; Anibal Ferreira; Joao M Frazao; Jose Dias Curto; Hartmut H Malluche
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

10.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-Jing Wang; Shobha Sahney; Barbara Gales; Robert M Elashoff; Harald Jüppner; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2009-03-20       Impact factor: 3.714

View more
  43 in total

1.  CKD-mineral and bone disorder: core curriculum 2011.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2011-10-21       Impact factor: 8.860

2.  New thoughts concerning the epidemic of rickets: was the role of alum overlooked?

Authors:  Russell W Chesney
Journal:  Pediatr Nephrol       Date:  2011-09-19       Impact factor: 3.714

Review 3.  Defective skeletal mineralization in pediatric CKD.

Authors:  Katherine Wesseling-Perry
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 4.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

Review 5.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

6.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

Review 7.  Treatment of hyperphosphatemia: the dangers of high PTH levels.

Authors:  Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2019-11-06       Impact factor: 3.714

8.  Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone.

Authors:  Renata C Pereira; Isidro B Salusky; Richard E Bowen; Earl G Freymiller; Katherine Wesseling-Perry
Journal:  Bone       Date:  2019-08-01       Impact factor: 4.398

Review 9.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

Review 10.  The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.

Authors:  Katherine Wesseling-Perry; Harald Jüppner
Journal:  Bone       Date:  2012-10-16       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.